K Pharma has entered into the license agreement with Alfresa Pharma Corporation

K Pharma has entered into an agreement with Alfresa Pharma Corporation, a subsidiary of Alfresa Holdings Corporation and a pharmaceutical and other manufacturing company, to grant development rights and manufacturing and marketing rights in Japan for ropinirole hydrochloride, which was discovered through drug discovery research using disease-specific iPS cells for the first time in the world as a treatment for amyotrophic lateral sclerosis ("ALS").